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Abstract
Transient receptor potential melastatin member 4 (TRPM4), a Ca2+-activated nonselective cation channel, has been
found to mediate cell membrane depolarization in immune response, insulin secretion, cardiovascular diseases, and
cancer. In murine experimental autoimmune encephalomyelitis (EAE), TRPM4 deletion and administration of
glibenclamide were found to ameliorate clinical symptoms and attenuate disease progression. However, the
exact role of TRPM4 in EAE, as well as the molecular mechanisms underlining TRPM4 contribution in EAE,
remain largely unclear. In the present study, EAE was induced in WT C57BL/6 N mice using myelin oligodendrocyte
glycoprotein 35–55 (MOG35–55) and TRPM4 protein and mRNA expression were examined in spinal cord membrane
extracts. Our results showed that TRPM4 protein and mRNA are upregulated in EAE, and that their upregulation
correlated with disease progression. Moreover, newly-developed TRPM4 inhibitors, named compound 5 and compound
6, were shown to exert a better neuroprotection compared to currently used TRPM4 inhibitors in an in vitro model of
glutamate-induced neurodegeneration. These results support the hypothesis that TRPM4 is crucial from early stages of
EAE, and suggest that these more potent TRPM4 inhibitors could be used as novel protective therapeutic tools in
glutamate-induced neurodegeneration.
Keywords: TRPM4, Experimental autoimmune encephalomyelitis, Glutamate-induced neurodegeneration, Multiple
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Introduction
Multiple sclerosis (MS) is a multifocal demyelinating dis-
ease of the central nervous system (CNS) leading to the
progressive destruction of the myelin sheath surround-
ing axons [1]. The hallmark of demyelinating disease is
the formation of the sclerotic plaque, which represents
the end of a pathological process involving inflamma-
tion, oligodendrocyte depletion, astrocytosis, and neur-
onal and axon degeneration [2]. Although the
mechanisms leading to the development of the disease
are not fully understood, numerous evidence indicates
that MS is an autoimmune disease, the initiation and
progression of which are dependent on an autoimmune
response against myelin antigens [3]. However, it is clear
that other, non-immunological factors are important in
this neurodegenerative process. Recent reports suggested
that changes in neuronal ion channel expression and/or
function are of pathophysiological importance, although
it seems that chronic inflammation is a prerequisite for
neurodegeneration at any stage of the disease [4]. One of
the central pathophysiological mechanisms leading to
axonal and cellular injury is intracellular Na+/Ca2+ over-
load to which neurons and oligodendrocytes demon-
strate a selective vulnerability [5]. Several ion transport
mechanisms that may contribute to toxic Na+/Ca2+ load-
ing include sodium channels, such as Nav1.2 and Nav1.6
[6, 7], acid-sensing ion channel 1 (ASIC1) [8, 9] and
Na+/Ca2+ exchanger (NCX) [10, 11]. Among them, re-
cent findings underlined the transient receptor potential
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melastatin 4 cation channel (TRPM4) as a key player in
neuronal degeneration in MS and experimental auto-
immune encephalomyelitis (EAE) [12]. TRPM4 is a
calcium-activated non-selective cation channel widely
expressed in several tissues and reported to be involved
in a variety of physiological and pathological processes,
including modulation of immune cells activity, such as
T-cells [13], mast cells [14] and dendritic cells [15], insu-
lin secretion by pancreatic β cells [16], mechano-trans
duction in cerebral arteries [17], Ca2+ signaling in cancer
[18], and several cardiac conduction disorders [19–22]
In addition, TRPM4 has been linked to several neuro-
logical disorders such as experimental autoimmune en-
cephalomyelitis and multiple sclerosis [12], spinal cord
injuries [23], and traumatic brain injuries [24]. Moreover,
it has been shown that pharmacological inhibition of
TRPM4 using the antidiabetic drug glibenclamide re-
sulted in reduced axonal and neuronal degeneration and
attenuated clinical disease scores in EAE [12, 24, 25].
In the present study, we first investigate TRPM4 expres-
sion in mouse spinal cords during myelin oligodendrocyte
glycoprotein (MOG)35–55 peptide-induced EAE. The re-
sults show that TRPM4 protein, as well as Trpm4 gene,
are upregulated in EAE, and that this increase correlates
with disease progression. Second, newly-developed
TRPM4 inhibitors, anthranilic amides named compound
5 and compound 6, are shown to be able to protect neur-
onal cells from glutamate-induced neurodegeneration,
confirming TRPM4 as a potential therapeutic target for
glutamate-induced neuronal cell death in EAE.
Material and methods
EAE induction
Female 10–12 weeks old WT C57BL/6 N mice were pur-
chased from Harlan Laboratories (Itingen, Switzerland) and
immunized subcutaneously in the lower back area with
200 μg MOG35–55 (Genscript, Piscataway, NJ, USA) in
complete Freund’s adjuvant containing 4 mg/ml heat-killed
Mycobacterium tuberculosis H37Ra (Difco, FranklinLakes,
NJ, USA). 200 ng of pertussis toxin (List Biological Labora-
tories, Campbell, CA, USA) were administered
intra-peritoneally on the day of immunization and 48 h later.
The mice were weighted and scored daily as follows: 0 = no
clinical deficits; 0.5 = tail paralysis; 1 = hind limb paresis; 1.5
= partial hind limb paralysis; 2 = full hind limb paralysis; 2.5
= full hind limb paralysis and forelimb paresis; 3 = premorbid
or dead. Mice with score ≥ 2.5 were sacrificed. As a control,
mice were immunized with complete Freund’s adjuvant
(CFA) without MOG peptide. At a specific day post
immunization, mice were sacrificed under terminal isofluor-
ane anesthesia, transcardially perfused with 100 mL 1X PBS
and spinal cords were removed. All animal experiments were
approved by the local ethics committee (Amt für Land-
wirtschaft und Natur des Kantons Bern; BE 139/14).
Cell transfection and antibody validation
In order to validate our anti-mouse TRPM4 antibody,
human embryonic kidney (HEK293) cells were pur-
chased from Sigma-Aldrich (Darmstadt, Germany), cul-
tured with Dulbecco’s modified Eagle’s culture medium
supplemented with 4 mM Glutamine, 10% FBS and a
cocktail of streptomycin-penicillin antibiotics and transi-
ently transfected with 300 ng of mouse TRPM4 WT
plasmid or empty vector (pcDNA4TO) in a P100 dish
(BD Falcon, Durham, North Carolina, USA) mixed with
30 μL of JetPEI (Polyplus transfection, Illkirch, France)
and 250 μL of 150 mM NaCl. A spinal cord sample from
a healthy C57BL/6 N WT mouse and the transfected
cells were then lysed with 1X lysis buffer [50 mM
HEPES pH 7.4; 150 mM NaCl; 1.5 mM MgCl2; 1 mM
EGTA pH 8.0; 10% Glycerol; 1% Triton X-100; 1X
Complete Protease Inhibitor Cocktail (Roche, Mann-
heim, Germany)] and protein expression was investi-
gated using Western Blot technique. The anti- mouse
TRPM4 antibody was generated by Pineda Antikorpen
(Berlin, Germany) using the following peptide sequence:
NH2-VGPEKEQSWIPKIFRKKVC-CONH2. A fraction
of the antisera, which was subsequently used in this
study, was affinity purified. The results of the antibody
validation are shown in Fig. 1c.
Membrane protein isolation and western blot
For membrane protein expression studies, spinal cords
were lysed with 1X lysis buffer and diluted 1 to 5 in a
1 M saccharose solution (1 M HEPES pH 7.4; 1 M sac-
charose; 1X Complete Protease Inhibitor Cocktail). Tis-
sue lysates were incubated overnight at 4 °C, centrifuged
at 3′000 g for 15 min to remove cellular fragments and
then ultra-centrifuged at 200′000 g for 40 min. Superna-
tants were collected and protein concentration was
assessed with the Bradford Assay using bovine serum al-
bumin as standard. Eighty μg of protein was loaded on
9% polyacrylamide gels, transferred with the TurboBlot
dry blot system (Biorad, Hercules, CA, USA) and de-
tected with anti-mouse TRPM4 (generated by Pineda,
Berlin, Germany), anti Na+/K+ ATPase α1 ab7671
(Abcam, Cambridge, UK) and anti α-actin A2066 (Sig-
ma-Aldrich, Darmstadt, Germany) antibodies using
SNAP i.d. (Millipore, Billerica, MA, USA). All the West-
ern Blots have been quantified using Image Studio Lite
software from LI-COR Biosciences (Lincoln, NE, USA)
and TRPM4 expression was normalized using Na+/K+
ATPase α1 for membrane fractions and α-actin for total
fractions.
Reverse transcription and quantitative real time PCR
Total RNA isolation was performed using TRIzol Re-
agent (Applied Biosystems, Foster City, CA, USA) as de-
scribed by the manufacturer. Concentration and purity
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of total RNA was determined by optical density meas-
urement using a NanoDrop 2000 spectrophotometer
(Thermo Scientific, Waltham, MA, USA). cDNA was
synthesized using High Capacity cDNA Reverse Tran-
scription kit (Applied Biosystems, Foster City, CA, USA)
and quantitative expression analysis was performed with
7500 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). Quantification of mRNA expres-
sion levels was investigated with TaqMan gene expres-
sion assay Mm01205532_m1 for mouse Trpm4, using
Gapdh TaqMan gene expression assay Mm99999915_g1
as a control. Relative expression of the studied gene was
calculated with the 2-ΔΔCt method.
Cell surface biotinylation assay
To study the expression at the plasma membrane, bio-
tinylation assay of membrane proteins was used. In this
assay, membrane proteins are labeled with biotin and
subsequently immunoprecipitated with streptavidin
beads to isolate the protein membrane fraction. Mouse
hippocampal HT22 cells (Merck Millipore, Burlington,
MA, USA), previously incubated with 1 mM glutamate
(Sigma Aldrich, Darmstadt, Germany), were treated with
EZlinkTM Sulfo-NHS-SS-Biotin (Thermo Scientific,
Waltham, MA, USA) 0.5 mg/mL in cold 1X PBS for
15 min at 4 °C. Subsequently, the cells were washed
twice with 200 mM Glycine in cold 1X PBS and twice
with cold 1X PBS to inactivate and remove the excess of
biotin, respectively. The cells were then lysed and centri-
fuged at 16′000 g at 4 °C for 15 min. Two milligrams of
the supernatant were incubated with 50 μL Streptavidin
Sepharose High Performance beads (GE Healthcare,
Uppsala, Sweden) for 2 h at 4 °C, while forty μg of pro-
tein were kept for the input fraction. The beads were
Fig. 1 TRPM4 expression analysis in spinal cords from EAE mice. Female C57BL/6 N WT mice were immunized with MOG35–55 peptide or with
CFA only. Clinical score (a) and body weight (b) were measured for 28 days after immunization. At day 28 post immunization, spinal cords were
extracted and membrane proteins were isolated. c Samples from HEK 293 cells transiently transfected with mouse TRPM4 WT plasmid or empty
vector (pcDNA4TO) and a spinal cord sample from a healthy WT C57BL/6 N were analyzed for TRPM4 expression, using alpha actin as loading
control. A TRPM4 band can be detected at 134 kDa. d TRPM4 membrane expression was analyzed with Western Blot, and alpha subunit of Na+/
K+ ATPase is used as a loading control and for TRPM4 normalization (e) qPCR analysis on Trpm4 gene expression in spinal cords from EAE mice
and healthy controls. Data are represented as relative mRNA expression and the expression of Gapdh is used as reference. f Data have been
analyzed using unpaired Student’s t-test and are represented as mean ± s.e.m. (*** P < 0.001)
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subsequently washed five times with 1X lysis buffer be-
fore elution with 50 μL of 2X NuPAGE sample buffer
(Invitrogen, Carlsbad, CA, USA) plus 100 mM DTT at
37 °C for 30 min.
Cellular neuroprotection assays
To assess the neuroprotective effect of TRPM4 blockers,
HT22 cells were incubated with different TRPM4 inhibitors
or 1% of their dissolving medium DMSO as control for 2 h
before incubation with 5 mM glutamate. Two well known
TRPM4 blockers, 9-phenantrol and glibenclamide, as well
as newly-developed blockers, such as 4-Chloro-2-(2-(2-chlo
rophenoxy)acetamido) benzoic acid, also called compound
5 or CBA, and 4-Chloro-2-(2-(naphthalene-1-yloxy) aceta-
mido) benzoic acid, also called compound 6 or NBA, were
used at 5 and 10 μM concentrations. Cell viability was
assessed using Tripan blue dye and the number of dead
cells was measured using Countess II FL Automated Cell
Counter (Thermo Scientific, Waltham, MA, USA). Values
were expressed as the percentage of survival compared to
untreated controls. Using the same procedure, cell integrity
was assessed using LDH-Cytotoxicity Assay kit II (Abcam,
Cambridge, UK) according to manufacturer instructions
and values were expressed as percentage of controls.
Statistical analysis
Western blot, qPCR and cell viability experiments were
analyzed using a Student’s t-test or one-way ANOVA
with Sidak’s correction for multiple comparison, with a
p-value < 0.05 considered as significant. Data are repre-
sented as the mean ± s.e.m. Correlation analyses were
performed with Spearman’s correlation analysis test.
GraphPad Prism version 7 (GraphPad Software, San
Diego, CA, USA) was used for the analysis. Statistical
post-hoc power calculation has been performed using
Stata 14.2 in experiments using three mice, and the re-
sults are uploaded as Additional file 1.
Results
Membrane expression of TRPM4 is increased in EAE
spinal cords
Female C57BL/6 N mice were immunized with MOG35–55
peptide or with CFA only as described in the ‘Material and
Methods’ section. Mice immunized with the MOG35–55
peptide exhibit the first clinical symptoms and body weight
loss around 10 days post immunization and a peak of the
disease was reached at day 15, while CFA-immunized ani-
mals did not show any relevant clinical phenotype (Fig. 1a
and b). At day 28 post immunization, animals were sacri-
ficed and the spinal cords were removed for mRNA and
protein expression analysis. Membrane expression of
TRPM4 was assessed, resulting in a significant higher pro-
tein band intensity in EAE animals compared to CFA con-
trols (Fig. 1d and f). We then performed qPCR on the
same spinal cord samples to determine whether this in-
crease in protein expression may have been due to in-
creased mRNA levels. Results in Fig. 1e revealed a
significant increase in Trpm4 gene expression in EAE com-
pared to healthy controls.
TRPM4 expression in spinal cords in EAE correlates with
disease stages
To further investigate the involvement of TRPM4 in
EAE, 18 female C57BL/6 N mice were immunized as de-
scribed previously and sacrificed on different days post
immunization reflecting different stages of the disease,
as shown in Table 1. EAE clinical score and body weight
are shown in Fig. 2a and b. After sacrifice, spinal cords
were collected and membrane protein lysates as well as
mRNA were prepared. Interestingly, an increase of
TRPM4 expression, compared to CFA controls, was
already detected at pre-clinical stage of EAE, and it be-
came more significant at the EAE acute phase. Consist-
ently, TRPM4 protein expression continued to increased
and reached the highest value at the chronic stage of
EAE (Fig. 2c and e). Together, TRPM4 mRNA expres-
sion was analyzed in the different EAE phases and also
resulted to correlate with disease stage (more advanced
EAE progression = higher Trpm4 gene expression), as re-
ported in Fig. 2d. Correlation analysis between disease
stage and TRPM4 mRNA expression, as well as protein
expression, has been performed, and it is shown in Fig.
2f and g, respectively. Spearman’s analysis resulted in a
coefficient (r) of approximately 0.6, supporting a correl-
ation between disease progression and TRPM4 mRNA
and protein expression.
Imbalanced glutamate metabolism does not alter TRPM4
expression
In a recent work, a mechanism of neurodegeneration in-
volving TRPM4 has been proposed and resulted to be
related to imbalanced glutamate metabolism. In inflam-
matory conditions (such as in multiple sclerosis), astro-
cytes release high amounts of glutamate, which in turn
induces neurodegeneration by eliciting Ca2+ and Na+ in-
flux. The increase in intracellular Ca2+ activates TRPM4,
and the TRPM4-mediated inward current causes cell
swelling and cell death [12]. In addition, it was reported
that hippocampal neurons from TRPM4 KO mice were
unaffected by glutamate exposure [12], consistent with a
model that neuronal death in EAE is mainly driven by
glutamate.
HT22 mouse hippocampal cells have been reported to
be a good model for glutamate-induced neurodegenera-
tion with involvement of TRPM4 [26]. In this work by
Cho and colleagues, HT22 cells exhibited an endogenous
TRPM4 activation after incubation with glutamate, and
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TRPM4 currents resulted to be inhibited by
9-phenantrol [26].
To investigate whether TRPM4 expression was modu-
lated by imbalanced glutamate metabolism, we incu-
bated HT22 cells with 1 mM glutamate and harvested
them at different time points after glutamate addition.
As shown in Fig. 3, addition of glutamate did not affect
TRPM4 protein expression, both in the total fraction
(Fig. 3a and c) and at the cell surface (Fig. 3b and d).
Hence, this suggested that glutamate is involved in
Table 1 Mice sacrifice at different EAE stages
Day of sacrifice Average clinical score EAE stage
Mice 1–3 Day 8 0 Immune activation but no EAE symptoms
Mice 4–6 Day 11 0.5 Weight loss and very early EAE symptoms
Mice 7–10 Day 14 1.5 Confirmed EAE symptoms
Mice 11–14 Day 18 2.5 EAE peak
Mice 15–18 Day 28 2.0 Chronic EAE symptoms
Fig. 2 TRPM4 expression in spinal cords from EAE mice correlates with disease stages. Female C57BL/6 N WT mice were immunized with MOG35–55
peptide or with CFA only and sacrificed at different days post immunization reflecting different EAE stages. Clinical score and body weight are represented
in panel a and b respectively. c and e TRPM4 protein expression at different EAE stages is shown as a relative intensity of protein band and alpha subunit
of Na+/K+ ATPase is used as a loading control and for TRPM4 normalization. d qPCR analysis on Trpm4 gene expression in spinal cords from EAE mice and
healthy control at different EAE stages. Data are represented as relative mRNA expression and the expression of Gapdh is used as reference. Data have
been analyzed using one-way ANOVA with Sidak’s correction for multiple comparison test and are represented as mean ± s.e.m. (** P< 0.01; *** P< 0.001).
Correlation between clinical score and TRPM4 mRNA (f) or TRPM4 protein expression (g) is calculated using Spearman’s correlation analysis. Spearman
correlation coefficients (r) and their corresponding p values are shown
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increased TRPM4 activation, but does not have any role
in increased TRPM4 expression at the cell membrane.
TRPM4 specific inhibitors attenuate in vitro glutamate-
induced neurodegeneration
Recently, due to a lack in specific TRPM4 inhibitors,
more selective and potent compounds have been synthe-
sized and screened using a fluorescence cell-based
screening assay [27]. From this screening, two promising
anthranilic amides analogs of flufenamic acid, named
compound 5 (4-Chloro-2-(2-(2-chlorophenoxy)aceta-
mido) benzoic acid, CBA) and compound 6 (4-Chlor-
o-2-(2-(naphthalene-1-yloxy) acetamido) benzoic acid,
NBA), have been identified, and resulted to have an IC50
of 1.5 ± 0.1 μM and 0.4 ± 0.3 μM respectively [27].
We then tested whether the newly-developed TRPM4
inhibitors could better attenuate glutamate-induced cell
death compared to commonly used compounds, such as
9-phenantrol and glibenclamide, both shown to exert a
neuroprotective effect by blocking TRPM4 activity [12, 25,
26, 28]. Neuronal cell death was induced in vitro by incu-
bating HT22 cells with 5 mM glutamate after a 2 hours
pre-incubation with 5 or 10 μM 9-phenantrol, glibencla-
mide, and the two newly-developed compound 5 and
compound 6. All compounds resulted to be well tolerate
and did not induce any cell death or loss of integrity in
HT22 cells without glutamate (Fig. 4a and b). As shown in
Fig. 4, all TRPM4 inhibitors protected neuronal cells
against cell death and loss of integrity induced by 5 mM
glutamate in a dose dependent manner. Moreover, com-
pound 5 and compound 6 exerted a more beneficial effect
compared to 9-phenantrol or glibenclamide, with a reduc-
tion of dead cells and LDH release of ̴ 40% (Fig. 4a and b).
Discussion
Multiple sclerosis is the most common autoimmune dis-
order of the central nervous system, affecting approxi-
mately 2.5 million people worldwide [1]. It is primarily
an inflammatory disorder of the brain and spinal cord in
which focal lymphocytic infiltration leads to damage of
myelin and axons; however, a growing body of evidence
suggests that non-immunological factors, such as
changes in neuronal ion channel expression and/or func-
tion, are of pathophysiological importance [29]. In a re-
cent study by Schattling and colleagues, TRPM4 was
found to be expressed in axons and neurons of mice and
humans, and suggested to mediate neurodegeneration by
contributing in glutamate-induced cell swelling and cell
death without affecting the immune response triggered
in the EAE model [12]. In addition, authors showed that
hippocampal neurons from TRPM4 KO mice were un-
affected by glutamate exposure, suggesting that
Fig. 3 Incubation of HT22 cells with 1 mM glutamate does not alter TRPM4 expression. HT22 cells were incubated with 1 mM glutamate and
harvested at different time points after glutamate addition. TRPM4 total (a) as well as surface (b) expression were evaluated, using alpha actin and
alpha subunit of Na+/K+ ATPase as loading controls and for TRPM4 normalization. c and d Total and surface TRPM4 protein expression are shown
as a relative intensity of protein band. No significant difference is reported (data are of three independent experiments)
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glutamate is a major contributor to neuronal cell death
in EAE involving TRPM4 [12].
In the present study, we reported that TRPM4 is not
only overexpressed in spinal cords from EAE mice com-
pared to healthy controls, but that its increased expres-
sion correlated with disease progression. We then
demonstrated that this increase in TRPM4 membrane
expression is due to an increase in Trpm4 gene expres-
sion. Moreover, it has been shown that during the late
stages of EAE, there is a transition from an inflamma-
tory phenotype to a non-remitting neurodegenerative
profile with CNS atrophy [30]. For this reason,
newly-developed TRPM4 inhibitors have been tested in
vitro to attenuate glutamate-induced neurodegeneration,
resulting in an increased cell integrity and survival, com-
pared to well-known TRPM4 blockers.
It is indeed evident that two parallel mechanisms involv-
ing TRPM4 are occurring in EAE: a first mechanism lead-
ing to increased TRPM4 expression at the cell membrane
and a subsequent one leading to increased channel
activation triggered by glutamate. It has been reported
that during EAE-dependent neuroinflammation, astro-
cytes activation causes high glutamate release leading to
increased extracellular glutamate concentration. High glu-
tamate levels induce neurodegeneration by eliciting Na+
and Ca2+ influx which, in turn, activates TRPM4 [31].
However, based on our findings, an increase in extracellu-
lar glutamate does not alter TRPM4 membrane expres-
sion, but only modulates its function. Together with an
increase in TRPM4 protein expression,Trpm4 gene seems
to be substantially upregulated, and its upregulation corre-
lates with the degree of inflammation and neurodegenera-
tion in EAE. Hence, an additional pathway leading to
increased Trpm4 gene expression is likely to occur.
Many gene expression studies have been undertaken
to look at the gene transcript levels in MS and EAE. In
general, genes showing variable expression included
mainly immunological and inflammatory genes, such as
genes encoding interleukin-6, interleukin-17 and
interferon-gamma [32, 33]. Interestingly, several genes
Fig. 4 Newly-developed TRPM4 inhibitors better attenuate glutamate-induced neurodegeneration compared to commonly used compounds. HT22 cells
were incubated with 5 mM glutamate after pre-incubation with 5 μM and 10 μM of commonly used TRPM4 inhibitors as well as newly-developed ones.
The bar graphs showed the results of cell viability (a) and LDH-release assays (b), where glutamate-induced cell death and membrane disruption were
prevented dose-dependently, with newly-developed compounds exerting a more beneficial effect. Data have been analyzed using one-way ANOVA with
Sidak’s correction for multiple comparison test and are represented as mean ± s.e.m. (** P< 0.01; *** P< 0.001; n= 10 for each condition)
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encoding proteins that play critical roles in ion homeo-
stasis, mitochondrial function and impulse conduction
have been shown to be dysregulated. In particular, tran-
script and protein levels of the Ca2+ ATPase 2 (PMCA2),
an ion pump involved in Ca2+ extrusion, were dramatic-
ally decreased in coincidence with the onset of clinical
symptoms in a rat model of EAE [34]. Together, genes
encoding sodium channels have been reported to be dys-
regulated in inflammatory conditions [34, 35]. The
mechanism by which this dysregulation of sodium chan-
nels occurred remains elusive. It has been hypothesized
that mediators such as nerve growth factor (NGF) or cy-
tokines released at the site of inflammation might be
transported to the innervating perikarya, resulting in the
stimulation of channel synthesis [36]. This mechanism
proposed by Mandel and colleagues could explain the
gene upregulation of sodium channels, and could be
used to explain Trpm4 upregulation in EAE. However,
further studies are required to address the exact molecu-
lar mechanism leading to Trpm4 gene expression in-
crease in EAE.
Together with an increase in Trpm4 gene expression,
subsequent mechanisms for increased TRPM4 mem-
brane expression and trafficking independent from the
transcriptional machinery can occur. It was reported
that in cardiac conduction disturbances with involve-
ment of TRPM4, where several genetic variants of the
channel were leading to an increase in the membrane
protein expression without affecting the gene expression
[19, 22]. This was due to altered half-life and/or post
translational modification (mainly SUMOylation) affect-
ing the trafficking and/or stability of the protein [19, 22].
In addition, TRPM4 was reported to be overexpressed in
prostate cancer, where its increased expression pro-
moted the stabilization and activity of β-catenin enhan-
cing cell proliferation, but the underlying mechanisms
have not yet been clarified [18]. Further, it has been
shown that a glutamate receptor-mediated intracellular
calcium rise activates the protein kinase C (PKC) path-
way, which could in turn influence TRPM4 trafficking to
the cell membrane [37]. Moreover, an increased sulfo-
nylurea receptor 1 (SUR1)-TRPM4 interaction has been
reported in spinal cords from EAE mice, suggesting a
possible role of this interaction in increased TRPM4 sur-
face expression [25]. Lastly, a recent work described that
14–3-3γ depletion reduced TRPM4 expression and at-
tenuated glutamate-induced neuronal cell death [26].
Hence, post-translational mechanisms are likely to occur,
together with increased TRPM4 gene expression, to en-
hance TRPM4 trafficking to the cell membrane. Once at
the membrane, TRPM4 is over-activated by increased
Ca2+ influx triggered by glutamate.
Expression of TRPM4 has been reported in neurons, and
they could be the origin of TRPM4 overexpression in spinal
cords of EAE mice. Alternatively, an increased TRPM4 ex-
pression could be due to differences in CNS-infiltrating im-
mune cells, although Schattling and colleagues did not
report any change in infiltrating cells between WT and
TRPM4 KO mice after EAE induction [12].
TRPM4 was found to be expressed in astrocytes and to
be involved in astrocyte swelling in several pathological
conditions, such as brain edema [38], and glaucoma [39].
In EAE and multiple sclerosis, TRPM4 channels were re-
ported to be predominantly expressed by reactive astro-
cytes in pathologically involved tissues that exhibit a
significant inflammatory burden, such as spinal cords [25].
Based on this observation, it was hypothesized that the
channel contributed to astrocyte-mediated inflammation
in EAE, and that in vivo treatment with TRPM4 blockers
would ameliorate clinical symptoms. Hence, astrocytes
could possibly be the cell population of the spinal cord
that contributes to increased TRPM4 expression.
In conclusion, accumulating evidence indicates a cru-
cial role of TRPM4 in EAE as well as in multiple scler-
osis, confirming TRPM4 as a strong potential
therapeutic target in these diseases. Despite that, add-
itional experiments are required to better understand
that molecular pathways of TRPM4 in neurological dis-
orders, such as multiple sclerosis.
Limitations of the study
This work is a mostly confirmatory study about the in-
volvement of TRPM4 in EAE, and it shows that TRPM4
inhibition can ameliorate glutamate-induced neurode-
generation; however, one can note some limitations.
First, the assumption that glutamate is the main con-
tributor to neuronal cell death in EAE involving TRPM4
remains a hypothesis, since, to date, we have no tools to
demonstrate it in vivo and to make a direct link between
the in vitro glutamate study and the in vivo EAE study.
Second, the WBs are membrane fraction preparations
from whole spinal cord tissue. Therefore, we cannot
identify the specific cell population responsible for
TRPM4 upregulation. Further studies are needed to ad-
dress these pending questions.
Additional file
Additional file 1: Post-hoc power calculation. Post-hoc power calculation
has been performed using Stata 14.2 to calculate statistical power of experi-
ments with three mice, both for mRNA as well as protein expression studies.
Results showed a 90% power with N/group = 2. (PDF 236 kb)
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